The mRNA technology faces growing doubts among Republicans, including people around President Donald Trump. Legislation aimed to ban or limit mRNA vaccines was in

Moderna (NasdaqGS:MRNA) recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®.

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term momentum without new products.

American pharmaceutical company Moderna (MRNA) is reportedly under scrutiny by U.S. President Donald Trump’s team, which is considering

HHS is re-evaluating a nearly $600 million contract with Moderna to develop and test vaccines against flu viruses that could prompt pandemics.

Arcturus Therapeutics believes it’s “highly unlikely” it will lose the promised government funding for its bird flu mRNA vaccine trial, despite reports swirling that Moderna’s own financial support | Arcturus believes it’s “highly unlikely” it will lose the government funding for its mRNA bird flu vaccine trial,

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic insider stock purchases

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore more details here.

Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded their patent litigation against Moderna internationally,